
结论很直接:这个市场不值得进入。 目前不是健康增长期,而是一个靠少数差异化单品撑起来的高筛选市场;对大品牌和小商家都不友好,小商家尤其不该进。
These products have successfully captured market share and are profitable. Their design and features are suggested for your investment, based on market competition, saturation, and demand.
Green indicates better success rate, red indicates poorer success rate. If you are a new brand, focus on the left side; if you are an old brand, focus on the right side.
结论很直接:你现在能进场,但这个市场不该进。 你的预算 50万 CNY 足够覆盖单个ASIN前期铺货、物流和初期推广,但从样本看这是一个高投入、强差异化、且利润极不稳定的市场,单靠这笔钱并不能形成长期护城河。
Alternative solutions may pose a risk to your investment in certain markets.
这个市场不值得进入,且对大品牌和小品牌都不友好。 现有样本里新品牌只有 HOMENURSE,结果一半成功、一半失败,但已经出现 28.5% 利润的产品也有直接亏损/无销量的新产品,说明这里不是稳定机会,而是靠单品打穿的高波动市场。
这不是一个适合进入的市场。 目前看到的不是“低门槛高回报”,而是一个对新卖家极不友好的筛选市场:样本里新品牌只有 HOMENURSE,盈利和亏损各 1 个,表面上是 50%/50%,但这只是极小样本,不能当成真实成功率;真正有竞争力的只有一款 B0GLGBHR24,另一款 B0H5JZTFVD 直接失败,说明同类新品并没有稳定的进入空间。
证据很明确:B0GLGBHR24 每月卖 700 件、月营收约 57,428 美元、利润率 28.5%、近期利润约 16,367 美元,早期投入约 59,491 美元,属于“要花钱做差异化才能跑出来”的产品;而失败款 B0H5JZTFVD 只是窄版折叠助行器,功能和竞品高度一致,几乎没有差异化,直接无销售。 这说明市场不是靠普通选品就能赢,而是靠功能创新、品牌背书和持续投放;对小品牌来说,如果没有明显结构创新和额外品牌预算,很难复制 B0GLGBHR24。按你的规则,28.5% 属于可接受利润,但只有这一款活着,说明不是普遍机会而是个别案例。更关键的是,当前没有看到 30~100+ 新品牌涌入的证据,但也没有看到足够多的新品牌成功样本;结合成功/失败各半、失败样本为零销量,结论仍然偏向“高风险、不可轻易进入”。
结论:不建议进入。 大品牌只有在愿意投入更高研发、品牌和推广预算时,才“可能”做出像 B0GLGBHR24 这样的结果;小品牌如果不走明显差异化路线,成功概率很低。可参考的正面样本是 HOMENURSE / B0GLGBHR24;需要避开的失败样本是 HOMENURSE / B0H5JZTFVD。
All products profit ratio distribution, including all products. For products with insufficient sales or missing profit ratio data, they will be categorized into other rows. This distribution included products that cannot determine the release date.
This are the profit ratios of all new products. There are products without sufficient sales, no more than 100pcs in 3 months, or no profit ratio data, or just released. Those will be considered as 'other'
Most profitable products ranked by profit value. Only includes products with positive profitability and active sales, regardless of release date.
![]() | B0GLGBHR24 | HOMENURSE | 2026-04-12 | Yes | $82.04 | 700pcs | $57428.0 | 28.5% | $16366.98 |
Most profitable new products ranked by profit value. Only includes newly released products with positive profitability and active sales.
![]() | B0GLGBHR24 | HOMENURSE | 2026-04-12 | Yes | $82.04 | 700pcs | $57428.0 | 28.5% | $16366.98 |
这不是适合进入的市场。 目前样本里新品牌只有HOMENURSE一个,结果是1个新品牌成功、1个新品牌失败,表面成功率50%,但关键是只有一个真正赚钱的新品,且失败款与成功款都来自同一品牌,说明新人不是普遍能赢,而是需要明确差异化和更强投入才能活下来。
What is the ratio of profitable products
What is the ratio of different brands owning all profitable new products
What is the ratio of different brands owning all nonprofitable new products
这个市场不适合入场,结论很明确:只有1个新品牌样本,成功率50%看起来不差,但实际已经暴露出“高预算+强差异化”才能活下来的特征,小品牌很难复制。 当前可见的赢家是 HOMENURSE 的 B0GLGBHR24:售价 74.99 美元,月销 700,月营收 57,428 美元,利润率 28.5%,但早期投入高达 59,490.70 美元,其中广告就占 13,379.46 美元;而同品牌另一款 B0H5JZTFVD 虽然也是新品牌新上架,却直接失败,属于无销量、无收益的非盈利产品,说明这不是“低门槛可复制”的市场,而是靠功能差异和资金堆出来的单品机会。
市场没有出现你要的小商家安全窗口,反而是明显的高投入筛选型市场。 从产品特征看,B0GLGBHR24 的成功来自“基于旧款做功能差异化”,目标人群明确,且白帽推广下仍需要较高的启动预算;B0H5JZTFVD 则是高度同质化的窄版助行器,直接失败。按你的规则,当前没有看到 30~100+ 新品牌涌入的饱和警报,但也没有看到健康的低成本机会:新品牌样本里只有 1 个盈利、1 个不盈利,成功率 50%;市场总体盈利率也是 50%,但样本极小,不能当成宽松信号。更关键的是,最近的唯一成功款是靠 105 条评论、28.5% 利润率、5.95 万美元早投才跑出来的,这更像“资金驱动的单品胜利”,不是普通小商家能轻松复制的路径。
建议:不要进。 大品牌如果一定要做,只能跟进 B0GLGBHR24 这种“功能差异化+高预算”路径,且起步预算要明显高于单纯采销/物流/前期投放能覆盖的水平;小商家不应进入,因为当前没有看到低评论、低预算、可复制的真实成功案例,反而更像需要持续投放和产品创新才能站住的市场。
Y-axis is product counts. X-axis is time period. For each time period, there are 2 column, each column is a released type of a product. Columns are in following orders: New product, New product on old listing
Y-axis is product counts. X-axis is time period. For each time period, there are 2 column, each column is a released type of a product. Columns are in following orders: New product, New product on old listing
Header is the profit ratios and first column is different time period. Each cells includes how many products are relased at the specific timerange and has a corresponding profit ratios. Only profitable and with active sales (more than 100 pcs in 3 months) will be considered. Any products without sufficient sold units in 3 months will be marked as 'other'.
| Time/Profit% | x < -10.0% | -10.0% <= x < 0.0% | 0.0% <= x < 10.0% | 10.0% <= x < 20.0% | 20.0% <= x < 30.0% | 30.0% <= x < 40.0% | x >= 40.0% | other |
|---|---|---|---|---|---|---|---|---|
| 2022 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2023 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2024 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2025 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2026 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
Header is the profit ratios and first column is different time period. Each cells includes how many products are relased at the specific timerange and has a corresponding profit ratios. Only profitable and with active sales (more than 100 pcs in 3 months) will be considered. Any products without sufficient sold units in 3 months will be marked as 'other'.
| Time/Profit% | x < -10.0% | -10.0% <= x < 0.0% | 0.0% <= x < 10.0% | 10.0% <= x < 20.0% | 20.0% <= x < 30.0% | 30.0% <= x < 40.0% | x >= 40.0% | other |
|---|---|---|---|---|---|---|---|---|
| 2025/8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2025/9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2025/10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2025/11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2025/12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2026/1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2026/2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2026/3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2026/4 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| 2026/5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2026/6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| 2026/7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |